Market Place
Sourcing Support
Patient put in critical condition by Neurogene gene therapy dies
23 Nov 2024 //
BIOSPACE
Neurogene Reports Q3 2024 Financial Results & Updates
18 Nov 2024 //
BUSINESSWIRE
Neurogene Details Gene Therapy Issue, Shares Plummet Again
18 Nov 2024 //
BIOSPACE
Neurogene Reports Positive NGN-401 Data in Pediatric Rett Syndrome
11 Nov 2024 //
BUSINESSWIRE
Voyager Therapeutics Announces Q3 2024 Conference Call & Webcast
05 Nov 2024 //
GLOBENEWSWIRE
Neurogene Presents Interim Data From NGN-401 Trial For Rett Syndrome
21 Oct 2024 //
BUSINESSWIRE
Neurogene Reports Q2 2024 Results And Recent Updates
09 Aug 2024 //
BUSINESSWIRE
Neurogene`s NGN-401 For Rett Syndrome Receives RMAT Designation
07 Aug 2024 //
BUSINESSWIRE
Neurogene to Participate in BMO Genetic Medicines Summit
02 Jul 2024 //
BUSINESSWIRE
Neurogene Announces Addition to Russell 3000® Index
01 Jul 2024 //
BUSINESSWIRE
Neurogene to Participate in Upcoming Conferences
05 Jun 2024 //
BUSINESSWIRE
FDA picks Denali, Neurogene and more for rare disease program
04 Jun 2024 //
FIERCE BIOTECH
Neurogene`s NGN-401 Rett Syndrome Gene Therapy In FDA START Program
03 Jun 2024 //
BUSINESSWIRE
Neurogene Q1 2024 Financials, Recent Updates
10 May 2024 //
BUSINESSWIRE
Neurogene Rett Data At ASGCT Annual Meeting
07 May 2024 //
BUSINESSWIRE
Neurogene Presenting NGN-401 Rett Syndrome Gene Therapy Safety Data
22 Apr 2024 //
BUSINESSWIRE
Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results
18 Mar 2024 //
BUSINESSWIRE
Neurogene Announces Expansion for Enrollment of Rett Syndrome Gene Therapy Trial
04 Mar 2024 //
BUSINESSWIRE
Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer
16 Jan 2024 //
BUSINESSWIRE
Neurogene Announces Business Update and 2024 Outlook
05 Jan 2024 //
BUSINESSWIRE
Neurogene Announces Closing of Merger with Neoleukin Therapeutics
19 Dec 2023 //
BUSINESSWIRE
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401
30 Nov 2023 //
BUSINESSWIRE
Neurogene inks Neoleukin reverse merger to fund gene therapies
18 Jul 2023 //
FIERCE BIOTECH
FDA clears Neurogene`s IND for NGN-101 Gene Therapy to Treat CLN5 Batten Disease
14 Sep 2021 //
BIOSPACE
Neurogene Announces EMA Grants Orphan Drug Designation to CLN5
29 Jun 2021 //
BUSINESSWIRE
Neurogene’s AAV Biodistribution Study Shows Route of Administration Essential
11 May 2021 //
BUSINESSWIRE
Neurogene and University of Edinburgh Announce Research Collaboration
20 Jan 2021 //
BUSINESSWIRE
Neurogene and University of Edinburgh Announce Research Collaboration
20 Jan 2021 //
BUSINESSWIRE
Neurogene and University of Edinburgh Announce Research Collaboration
18 Jan 2021 //
BUSINESSWIRE
Neurogene adds another $115M to the pot for trials for its gene therapies
17 Dec 2020 //
FIERCEBIOTECH
Neurogene Closes $115 Million Series B Financing
15 Dec 2020 //
BUSINESSWIRE
Neurogene Announces EMA Grants Orphan Drug Designation Gene Therapy
03 Dec 2020 //
BUSINESSWIRE
Neurogene Appoints Industry Veteran Robert A. Baffi, Ph.D. to Board of Directors
16 Sep 2020 //
BUSINESSWIRE
